Business
Creo Medical receives King’s Award for Enterprise
Creo Medical receives King’s Award for Enterprise.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\n\nCreo Medical Group plc\n(\"Creo\" the \"Company\" or the \"Group\")\n \nCreo Medical receives King's Award for Enterprise in Innovation\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, announces that it is to receive a King's Award for Enterprise in Innovation, at an event to be held at Windsor Castle on 9 July 2024.\n \nEstablished by Royal Warrant in 1965, The King's Awards for Enterprise is the UK's most prestigious business awards to recognise and encourage achievements in the fields of Innovation, International Trade, Sustainable Development and Promoting Opportunity through social mobility.\n \nDuring the reception, His Majesty will meet Creo's Chief Executive Officer, Craig Gulliford, as well as a diverse group of winners from across the United Kingdom, with recipients of the award able to use The King's Awards emblem for the next five years on their products and to promote their services.\n \n\n \nCreo Medical Group plc is an innovative and growing medical technology company. It has developed CROMA, an advanced energy electrosurgical platform and a range of novel, miniaturised devices that are used through the small working channels of endoscopes, enabling the most minimally invasive surgery where operations are performed from inside the body. Creo's Speedboat device harnesses CROMA's cutting and coagulation capabilities to remove cancerous and pre-cancerous growths and complex lesions in the bowel, oesophagus and stomach. By providing a solution that reduces the risks associated with conventional surgical procedures, Creo's Speedboat allows clinicians to precisely lift, resect and coagulate tissue with a single device, removing lesions from within the gastrointestinal tract in one piece. This means patients can be treated as day cases under mild sedation instead of more invasive surgery requiring general anaesthetic and multiple days in hospital.\n \nCreo's products deliver benefits to patients, reduce waiting lists, free up resources, and significantly lower hospital costs. NHS Supply Chain recently confirmed net cash savings of £687k were generated for an NHS Trust from 130 procedures using Creo's core Speedboat technology. Creo's technology is patent protected, and its devices are used da...